Indian Biosciences (INB) has successfully completed the DNA
identification of charred remains of victims of a cargo transport
airplane that crashed in the mountains to the east of Afghanistan’s
capital Kabul, in 2010.
The DNA identification profiles for all the samples were prepared and
matched as per FBI Laboratory’s Combined DNA Index System (CODIS)
Dr KS Mehta, director, Indian Biosciences, said, “The DNA
identification and matching was carried out successfully and the
families of the victims have received their rightful remains.”
Neeman assigns experts for trials
Max Neeman International, a clinical research services company in
India, has established a team of experts specialized in carrying out
rare disease trials in response to sponsor demand.
Max Neeman has been focusing on rare disease trials, in addition to
other indications. Patient enrollment for rare disease, complex global
and multi-centric trials is challenging because potential subjects are
fewer in number and widely dispersed. India has evolved into a
preferred destination for conducting such trials because of low-cost
and faster patient recruitment supported by the country’s diverse gene
pool and vast population.
Pharma files for IPO
Intas Pharmaceuticals has filed its draft red herring prospectus with
Securities and Exchange Board of India (SEBI) for an initial public
offering of its equity shares of face value $ 0.22 (
10) each comprising a fresh issue of
Equity Shares aggregating up to $95.5 million (
425 crores) and an Offer for Sale of
5,810,550 Equity Shares by Mozart Limited. The Issue, will be made
through a 100 percent book building process wherein not more than 50
percent of the issue shall be allocated on a proportionate basis to
qualified institutional buyers, not less than 15 percent of the Issue
shall be allocated to non-institutional bidders and not less than 35
percent of the issue shall be available to retail individual bidders.
Ecron acquires stake
Ecron Acunova (EA), a full-service CRO, announced the acquisition of
majority stake of aCROnordic, a CRO specialized in clinical research in
Denmark, Sweden, Finland and Norway, with its headquarters in Denmark.
Mr Soren Stroh, founder of aCROnordic, continues his role as CEO for
Mr DA Prasanna, founder and chairman of Ecron Acunova, said, “A recent
change in the strategy of sponsors in the healthcare industry asks for
more global presence of preferred provider CROs. The merger of EA and
aCROnordic will yield substantial synergy to both of us for serving our
enters phase III trials
Bharat Biotech, a multidimensional biotechnology company in India, has
initiated a phase III clinical trial in India with Clot-Busting Drug
THR-100 (Staphylokinase), a thrombolytic agent for the treatment of
The company is going in for trial in India with THR-100 in patients
suffering an acute myocardial infarction (AMI or heart attack). The
trial is expected to recruit approximately 120 patients.
Earlier, Bharat Biotech had entered into a license agreement with
ThromboGenics for the manufacture, clinical development and
commercialization of THR-100 with the objective of potentially
commercializing it as a replacement for established thrombolytics, such
as streptokinase and urokinase, in developing markets in December 2006.
The novel variant of recombinant staphylokinase, THR-100 is developed
for the treatment of AMI and other vascular diseases, based on its
ability to dissolve blood clots.
According to the company sources, the phase III trial with THR-100 is
anticipated to be completed in the second half of 2011.
The results of this phase III trial will later pave the way for this
thrombolytic to be filed for
marketing approval by Bharat Biotech with Indian regulatory authorities.
Biotec signs new deal
Panacea Biotec has signed a non-exclusive marketing agreement with
Laboratorios Clausen of Uruguay. The agreement will give an
access to Laboratorios Clausen to market Panacea Biotec’s Tacrolimus
(Pangraf) in few markets in Europe.
The agreement was signed in presence of His Excellency Mr Danilo
Astori, vice president of the Oriental Republic of Uruguay, who was in
India on an official visit to sign economic pact. In a separate
agreement of technology exchange, Panacea Biotec agreed to explore the
possibility of technology transfer of its product to Laboratorios
Clausen manufacturing facility and for subsequent marketing in Latin
Aurobindo Pharma announced that the company has received final approval
from the US FDA to manufacture and market Fosinopril Sodium tablets USP
10mg, 20mg and 40mg.
The product falls under the cardiovascular (CVS) therapeutic category.
The product has a market size of approximately $20 million for the 12
months ending September 2010 according to IMS and will be launched
Aurobindo now has a total of 134 ANDA approvals (102 Final approvals
and 32 Tentative approvals) from USFDA
Fortis signs pact
Fortis Healthcare (India), a fast growing hospital network and
TotipotentRX Cell Therapy, a US-based provider of cutting-edge
technologies in the stem cell and regenerative medicine market,
announced a collaboration to set up centers of excellence offering
cellular therapies and stem cell clinical trials, across select Fortis
hospitals. These centers will undertake stem cell clinical research
procedures relating to diabetes, cancer, cardiovascular disease, and
neurological ischemia. TotipotentRX will also set up state-of-the-art
cGMP laboratories in select hospitals, for processing stem cells before
transplantation to patients.
report for 20,000
Pune-based Acton Biotech recently launched its full genome scan which
will primarily look at giving a detailed genetic report of a person.
This full genome scan costs $447 (
20,000) and it takes one month to prepare
the report. This will contain information about a person’s genes, the
diseases he might have in his life span and a list of drugs that will
be in-efficacious or may cause severe side-effects. In addition to
this, regular updates will be sent to the person as and when research
laboratories find something new in his genes. The procedure involves
collection of a person’s blood sample at collection center across
cities which is subsequently sent to Acton’s facility in Pune, where
extraction and quality control checks of the sample will be done.
sets up its largest R&D lab in Bangalore
Agilent Technologies has expanded its life sciences and chemical
analysis center of excellence in Bangalore. The company also opened a
life sciences application development lab to accelerate the discovery
of life sciences analysis workflows. Together, the center and lab cover
8,000 sq.ft., making this the largest Agilent research facility in the
Agilent application scientists engaged in pharma, biopharma and other
life science applications, staff the facility and work hand-in-hand
with customers, thereby having access to critical samples and learning
about emerging application needs. The Bangalore Center of Excellence is
modeled on the same standards as other Agilent centers, with an
emphasis on Agilent's global environmental, health and safety
ILS joins hands
with Affymetrix for microarray solutions
Imperial Life Sciences (ILS), has tied up with Affymetrix, a US-based
microarray technology provider. From small personalized microarray
platform (GeneAtlas) and versatile microarray instrumentation (GeneChip
3000 7G) to fully-automated microarray instrument (GeneTitan),
Affymetrix has products for automated solutions to scientists. With
this agreement, ILS is looking forward to take the wide range of
microarray platforms and arrays for multiple applications like gene
expression studies, SNP genotyping, resequencing analysis, CHIP-on-chip
studies to its clients.
Affymetrix has more than 425 patents and 1,800 systems installed
worldwide. ILS hopes that the collaboration will help the company
provide world-class service and support to its customers.